NCT05705635

A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

A Multicenter, Randomized, Controlled Phase II Clinical Study of Comparison of Docetaxel for Injection (Albumin-bound) and Taxotere in Second-line or Above Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This trial is a multicenter, randomized, controlled clinical study to evaluate the efficacy and safety of Docetaxel for Injection (Albumin-bound) and Taxotere in locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.

Detailed description

One hundred patients with locally advanced or metastatic gastric adenocarcinoma or gastric esophageal junction adenocarcinoma will be randomly assigned to the test group or the control group. All patients will receive Docetaxel for injection (Albumin-bound) or Taxotere for treatment until disease progression. Regular visits and imaging examinations will be conducted to compare the efficacy and safety of the two groups.

Conditions

• Gastric Adenocarcinoma
• Adenocarcinoma of Gastroesophageal Junction

Interventions

Type	Name	Description
DRUG	Docetaxel for injection (Albumin-bound)	Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.
DRUG	Taxotere	Taxotere, by intravenous infusion, every 3 weeks.

Timeline

• Start date: 2023-01-13
• Primary completion: 2023-05-01
• Completion: 2024-12-01
• First posted: 2023-01-31
• Last updated: 2023-01-31

Locations

1 site across 1 country: China